The Sletten Group takes advantage of the self-association of fluorinated compounds to engineer and/or target new smart, personalizable nanotherapeutics. These endeavors involvethe synthesis of fluorous-soluble fluorophores, photosensitizers, and pharmaceuticals. Simultaneously, we develop new polymers to stabilize and target the fluorous payloads in vivo. We bring these advances together to result in a modular platform for nanotherapeutics. We are particularly interested in triggered therapies such as photodynamic therapy.